Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00DBE
|
|||
| Former ID |
DNC004504
|
|||
| Drug Name |
CI-1018
|
|||
| Synonyms |
CI-1018; UNII-Y4O6325SYW; Y4O6325SYW; CHEMBL111925; DSSTox_CID_27248; DSSTox_RID_82208; DSSTox_GSID_47248; SCHEMBL185627; CAS-NOCAS_47248; DTXSID0047248; NOCAS_47248; Tox21_300203; BDBM50217550; NCGC00254191-01; NCGC00247925-01; 179024-48-7; PD-168787; (+)-CI-1018; CI-1018, (+)-; UNII-05127JZ9KQ component KYFWUBJMTHVBIF-QFIPXVFZSA-N; 4-Pyridinecarboxamide, N-(3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrolo(3,2,1-jk)(1,4)benzodiazepin-3-yl)-, (R)-; 4-Pyridinecarboxamide, N-((3R)-3,4,6,7-tetrahydro-9-methyl-4-oxo-1-phenylpyrrol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H20N4O2
|
|||
| Canonical SMILES |
CC1=CC2=C3C(=C1)C(=NC(C(=O)N3CC2)NC(=O)C4=CC=NC=C4)C5=CC=CC=C5
|
|||
| InChI |
1S/C24H20N4O2/c1-15-13-18-9-12-28-21(18)19(14-15)20(16-5-3-2-4-6-16)26-22(24(28)30)27-23(29)17-7-10-25-11-8-17/h2-8,10-11,13-14,22H,9,12H2,1H3,(H,27,29)/t22-/m0/s1
|
|||
| InChIKey |
KYFWUBJMTHVBIF-QFIPXVFZSA-N
|
|||
| CAS Number |
CAS 179024-48-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
| Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [2] | |
| Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Purine metabolism | |||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | DARPP-32 events | |||
| G alpha (s) signalling events | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| TSH signaling pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010034) | |||
| REF 2 | New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.